Core Viewpoint - Shenzhou Cell's stock has shown significant volatility, with a year-to-date increase of 40.52%, but recent declines in the short term raise concerns about its performance [1][2]. Company Overview - Shenzhou Cell, established on April 23, 2007, and listed on June 22, 2020, is based in Beijing and focuses on the research and commercialization of biopharmaceutical products for various diseases, including cancer and autoimmune disorders [1]. - The company's main business revenue is derived entirely from product sales [1]. Financial Performance - For the period from January to September 2025, Shenzhou Cell reported a revenue of 1.312 billion yuan, a year-on-year decrease of 32.27%, and a net profit attributable to shareholders of -251 million yuan, reflecting a significant decline of 267.17% [2]. - As of September 30, 2025, the number of shareholders increased by 40.96% to 13,700, while the average circulating shares per person decreased by 29.06% to 32,390 shares [2]. Stock Market Activity - As of November 10, Shenzhou Cell's stock price was 50.91 yuan per share, with a market capitalization of 22.672 billion yuan [1]. - The stock has experienced a net outflow of 4.3243 million yuan in principal funds, with significant buying and selling activity from large orders [1]. - The stock has appeared on the "Dragon and Tiger List" three times this year, with the most recent instance on July 4, where it saw a net purchase of 87.5322 million yuan [1]. Shareholder Composition - As of September 30, 2025, the sixth-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 4.6168 million shares as a new shareholder [2]. - The seventh-largest shareholder is Southern CSI 500 ETF, which reduced its holdings by 93,400 shares [2]. - The tenth-largest shareholder is Innovation Drug, also a new entrant with 1.7893 million shares [2].

Core Points - The company will hold a Q3 2025 earnings presentation on November 17, 2025, from 10:00 to 11:00 AM [2][4] - The presentation will be conducted in an online interactive format, allowing investors to engage and ask questions [3][5] - Investors can submit questions from November 10 to November 14, 2025, through the Shanghai Stock Exchange's roadshow center or via the company's email [2][5] Meeting Details - The meeting will take place on November 17, 2025, from 10:00 to 11:00 AM [4] - It will be held online via the Shanghai Stock Exchange's roadshow center [4][5] - Key participants include the company's Chairman and General Manager, Dr. Xie Liangzhi, and other senior executives [4] Investor Participation - Investors can join the earnings presentation online on the specified date and time [5] - Questions can be pre-submitted through the roadshow center or the company's email before the deadline [5] Contact Information - The contact department for inquiries is the Securities Department, reachable at 010-50812198 [6] - Additional inquiries can be directed to the company's email: ir@sinocelltech.com [7]

Core Viewpoint - The company, Beijing Sinocell Technology Group Co., Ltd., is set to hold a Q3 2025 earnings presentation on November 17, 2025, to discuss its operational results and financial status with investors [2][3][4]. Group 1: Meeting Details - The earnings presentation will take place on November 17, 2025, from 10:00 to 11:00 AM [4]. - The format of the meeting will be an online text interaction, hosted on the Shanghai Stock Exchange's roadshow center [4][5]. - Participants will include the company's Chairman and General Manager, Dr. Xie Liangzhi, along with other key executives [4]. Group 2: Investor Participation - Investors can participate in the earnings presentation by logging into the Shanghai Stock Exchange's roadshow center on the scheduled date [5]. - A pre-question submission period is available from November 10 to November 14, 2025, allowing investors to submit questions via the roadshow center or the company's email [5]. Group 3: Contact Information - The contact department for inquiries is the Securities Department, reachable at phone number 010-50812198 and email ir@sinocelltech.com [7].

投资者可于 2025 年 11 月 10 日（星期一）至 11 月 14 日（星期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@sinocelltech.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 证券代码：688520 证券简称：神州细胞 公告编号：2025-041 北京神州细胞生物技术集团股份公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 线上文字互动平台：上海证券交易所上证路演中心（https://roadshow.ss einfo.com/） （三）线上文字互动平台：上海证券交易所上证路演中心（http://roadshow. sseinfo.com/） 三、参加人员 公司董事长兼总经理谢良志博士，董事、副总经理、董事会秘书唐黎明先生， 财务总监马洁女士，独立董事贾凌云女士（如有特殊情况，参会人员可能进行调 整）。 北京神州细胞生物技术集团股份公司（以下简称"公司"）已于 2025 ...

Group 1 - The core viewpoint of the article highlights a collective decline in the A-share market for innovative drug concept stocks, with significant drops in several companies [1] Group 2 - Changshan Pharmaceutical experienced a decline of over 19%, with a total market capitalization of 51.7 billion and a year-to-date increase of 181.54% [2] - Zicheng Pharmaceutical and Baiyang Pharmaceutical both fell by over 7%, with market capitalizations of 6.984 billion and 13.3 billion respectively, and year-to-date increases of 68.53% and 9.05% [2] - Other companies such as Bibete-U, Kangchen Pharmaceutical, and Kanghong Pharmaceutical saw declines exceeding 5%, with market capitalizations of 14.3 billion, 28.8 billion, and respective year-to-date increases of 79.30% and 62.53% [2] - The article also notes that MACD golden cross signals have formed, indicating potential upward momentum for some stocks [1]

Group 1 - Shenzhou Cell (688520.SH) reported its Q3 2025 results, with 17 institutional investors holding a total of 332 million shares, representing 74.53% of the company's total share capital [1] - The top ten institutional investors collectively hold 74.49% of the shares, with a slight decrease of 0.64 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, one fund, namely the Innovative Medicine fund, increased its holdings, while two funds, including Southern CSI 500 ETF and Galaxy Quantitative Preferred Mixed A, reduced their holdings [2] - Six new public funds were disclosed this period, including Qianhai Kaiyuan Refinance Stock and Zheshang Smart Selection Leading Three-Year Holding Period A [2] - A total of 258 public funds were not disclosed this period, including China Europe Medical Health Mixed A and China Merchants National Bio-Medical Index A [2]

Group 1 - The core viewpoint of the article highlights that Shenzhou Cell reported a significant decline in revenue and incurred losses in the third quarter of 2023 [1] - For the first three quarters of 2025, the company's revenue was approximately 1.312 billion yuan, representing a year-on-year decrease of 32.27% [1] - The net profit attributable to shareholders of the listed company was a loss of approximately 251 million yuan, with basic earnings per share reflecting a loss of 0.6 yuan [1] - As of the report, Shenzhou Cell's market capitalization stood at 23.6 billion yuan [1]

Core Viewpoint - Shenzhou Cell is a leading innovative biopharmaceutical company in China, focusing on the research and development of biological drugs across various therapeutic areas, including malignant tumors and autoimmune diseases [1] Group 1: Business Performance - For Q3 2025, Shenzhou Cell reported revenue of 1.312 billion yuan, ranking 10th among 34 companies in the industry, with the industry leader, Changchun High-tech, generating 9.807 billion yuan [2] - The net profit for the same period was -251 million yuan, placing the company 31st in the industry, while the top performer, Tonghua Dongbao, achieved a net profit of 1.188 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, Shenzhou Cell's debt-to-asset ratio was 101.46%, a decrease from 104.24% year-on-year, but still significantly higher than the industry average of 26.88%, indicating substantial debt pressure [3] - The gross profit margin for the same period was 94.09%, slightly down from 96.28% year-on-year, yet above the industry average of 70.17%, reflecting strong profitability potential [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 40.96% to 13,700, while the average number of circulating A-shares held per shareholder decreased by 29.06% to 32,400 [5] - Notable changes among the top ten circulating shareholders include the entry of Hong Kong Central Clearing Limited and the South China CSI 500 ETF, while the China Europe Medical Health Mixed A fund exited the list [5] Group 4: Market Outlook - According to West Securities, Shenzhou Cell's revenue in the first half of 2025 was below expectations due to price reductions from centralized procurement and medical insurance controls affecting its core product, Anjiah [6] - Despite challenges, the company is expected to see growth from new products and a stable increase in sales of other antibody drugs, with projected revenues for 2025-2027 of 2.194 billion, 2.543 billion, and 3.021 billion yuan, respectively [6] - Zhongyou Securities anticipates a revenue increase in 2024, with a forecast of 2.827 billion yuan for 2025, and a net profit of 223 million yuan, maintaining a "buy" rating [6]

Core Viewpoint - Shenzhou Cell (688520.SH) reported a significant decline in revenue and net profit for Q3 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company's operating revenue for Q3 2025 was 340 million yuan, representing a year-on-year decrease of 46.25% [1] - The net profit attributable to shareholders of the listed company was -217 million yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -164 million yuan [1]

Financial Performance - The company's operating revenue for the third quarter was ¥339,860,646.36, a decrease of 46.25% compared to the same period last year[3]. - The total profit for the third quarter was -¥217,421,450.38, with a year-to-date total profit of -¥251,279,601.67[3]. - The net profit attributable to shareholders for the third quarter was -¥216,901,236.46, and -¥250,672,332.75 year-to-date[3]. - Total operating revenue for the first three quarters of 2025 was approximately ¥1.31 billion, a decrease of 32.3% compared to ¥1.94 billion in the same period of 2024[16]. - Net profit for the first three quarters of 2025 was a loss of approximately ¥251.28 million, compared to a profit of ¥150.41 million in 2024[17]. - The company recorded a total comprehensive loss of approximately ¥251.19 million in 2025, compared to a total comprehensive income of ¥150.44 million in 2024[17]. Research and Development - Research and development expenses totaled ¥203,990,325.36 for the quarter, accounting for 60.02% of operating revenue, an increase of 25.99 percentage points[4]. - Research and development expenses for the first three quarters of 2025 were approximately ¥581.82 million, a decrease of 13.3% from ¥671.79 million in 2024[16]. Assets and Liabilities - Total assets increased to ¥3,761,436,578.09, representing a 14.54% increase from the end of the previous year[4]. - The company's current assets totaled CNY 1,826,472,317.93, up from CNY 1,460,622,848.37 in the previous period, reflecting a growth of approximately 25.1%[12][13]. - Total liabilities reached CNY 3,816,211,088.58, compared to CNY 3,149,055,574.41, reflecting an increase of approximately 21.2%[14]. - The company's short-term borrowings surged to CNY 1,762,437,408.90 from CNY 1,077,987,553.63, a significant increase of about 63.5%[13][14]. - The total equity attributable to shareholders decreased to CNY -48,211,427.97 from CNY 140,896,888.73, indicating a decline in shareholder equity[14]. - The total liabilities to equity ratio has increased, indicating a higher leverage position for the company compared to the previous period[14]. Cash Flow - The cash flow from operating activities for the year-to-date was -¥306,820,436.08[4]. - The company reported a net cash outflow from operating activities of approximately ¥306.82 million in 2025, down from a cash inflow of ¥189.69 million in 2024[19]. - Cash inflow from investment activities was approximately ¥1.13 billion in 2025, compared to ¥752.09 million in 2024[19]. - Net cash inflow from financing activities was approximately ¥736.77 million in 2025, significantly higher than ¥159.75 million in 2024[20]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,749[9]. - The largest shareholder, Lhasa Ailike Investment Consulting Co., Ltd., held 60.90% of the shares[9]. Earnings Per Share - The company reported a basic earnings per share of -¥0.50 for the third quarter and -¥0.60 year-to-date[3]. - Basic and diluted earnings per share for the first three quarters of 2025 were both -¥0.60, compared to ¥0.34 in 2024[17]. Sales and Revenue Decline - The company experienced a decline in sales revenue due to price reductions of its core product, Anjiajin®[7]. - Total operating costs increased to approximately ¥1.49 billion in 2025, up 2.2% from ¥1.46 billion in 2024[16]. Cash and Cash Equivalents - Cash and cash equivalents increased to CNY 396,498,224.09 from CNY 314,933,923.79, representing a rise of about 26%[12]. - Cash and cash equivalents at the end of the third quarter of 2025 totaled approximately ¥396.50 million, an increase from ¥340.44 million at the end of the same period in 2024[20]. Inventory and Accounts Receivable - Accounts receivable rose to CNY 688,905,342.85, compared to CNY 649,386,298.44, indicating an increase of approximately 6.1%[12]. - Inventory levels increased to CNY 326,970,398.21 from CNY 259,486,715.96, marking a growth of around 26%[12][13]. Non-Current Assets - The company reported a total non-current asset value of CNY 1,934,964,260.16, up from CNY 1,823,373,569.25, showing an increase of approximately 6.1%[13].